8-K current report · filed Aug 13, 2026

Assembly Biosciences Inc (ASMB) 8-K Current Report: August 13, 2026

Item 2.02Item EX-99.1ASMB overview

Short answer

Assembly Biosciences Inc (ASMB) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Assembly Biosciences’ quarter ended June 30, 2026.

Assembly Biosciences Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Assembly Biosciences’ quarter ended June 30, 2026
  • Exhibit 99.1 contains the company’s financial results and management commentary
  • Quarterly results may affect valuation, liquidity expectations and biotechnology development funding assessment

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up adjustment tied to Gilead activities
  • Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, supported by higher revenue and interest income
  • Cash, equivalents and marketable securities $320.4M, with runway projected into 2029 including Gilead’s $75M Q4 extension payment
  • ABI-6250 Phase 2 expansion into PBC and PSC targeted for Q1 2027, broadening the liver-disease opportunity beyond HDV
  • GS-1179 Phase 2 expected by year-end 2026, with an opt-in decision on 40% U.S. cost-profit sharing due by year-end

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Assembly Biosciences Inc 8-K filings

Get the next ASMB 8-K as it lands

Follow ASMB for push alerts, or ask the research agent what this filing means.